These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9270561)

  • 1. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.
    van Oosten BW; Lai M; Hodgkinson S; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Rudge P; McDougall A; McLeod JG; Adèr HJ; Polman CH
    Neurology; 1997 Aug; 49(2):351-7. PubMed ID: 9270561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate.
    Moreland LW; Pratt PW; Mayes MD; Postlethwaite A; Weisman MH; Schnitzer T; Lightfoot R; Calabrese L; Zelinger DJ; Woody JN
    Arthritis Rheum; 1995 Nov; 38(11):1581-8. PubMed ID: 7488278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412.
    Llewellyn-Smith N; Lai M; Miller DH; Rudge P; Thompson AJ; Cuzner ML
    Neurology; 1997 Apr; 48(4):810-6. PubMed ID: 9109860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis.
    Lindsey JW; Hodgkinson S; Mehta R; Siegel RC; Mitchell DJ; Lim M; Piercy C; Tram T; Dorfman L; Enzmann D
    Neurology; 1994 Mar; 44(3 Pt 1):413-9. PubMed ID: 8145907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.
    van der Lubbe PA; Dijkmans BA; Markusse HM; Nässander U; Breedveld FC
    Arthritis Rheum; 1995 Aug; 38(8):1097-106. PubMed ID: 7639806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
    Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA
    J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees.
    Jonker M; Slingerland W; Treacy G; van Eerd P; Pak KY; Wilson E; Tam S; Bakker K; Lobuglio AF; Rieber P
    Clin Exp Immunol; 1993 Sep; 93(3):301-7. PubMed ID: 8103714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis.
    Tak PP; van der Lubbe PA; Cauli A; Daha MR; Smeets TJ; Kluin PM; Meinders AE; Yanni G; Panayi GS; Breedveld FC
    Arthritis Rheum; 1995 Oct; 38(10):1457-65. PubMed ID: 7575695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis.
    van der Lubbe PA; Reiter C; Breedveld FC; Krüger K; Schattenkirchner M; Sanders ME; Riethmüller G
    Arthritis Rheum; 1993 Oct; 36(10):1375-9. PubMed ID: 8216397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis.
    Moreland LW; Bucy RP; Tilden A; Pratt PW; LoBuglio AF; Khazaeli M; Everson MP; Daddona P; Ghrayeb J; Kilgarriff C
    Arthritis Rheum; 1993 Mar; 36(3):307-18. PubMed ID: 8095785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients.
    Rumbach L; Racadot E; Armspach JP; Namer IJ; Bonneville JF; Wijdenes J; Marescaux C; Herve P; Chambron J
    Mult Scler; 1996 Feb; 1(4):207-12. PubMed ID: 9345436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.
    van Oosten BW; Lai M; Barkhof F; Miller DH; Moseley IF; Thompson AJ; Hodgkinson S; Polman CH
    Mult Scler; 1996 Jul; 1(6):339-42. PubMed ID: 9345413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action.
    van der Lubbe PA; Reiter C; Miltenburg AM; Krüger K; de Ruyter AN; Rieber EP; Bijl JA; Riethmüller G; Breedveld FC
    Scand J Immunol; 1994 Mar; 39(3):286-94. PubMed ID: 8128188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis.
    Moreland LW; Pratt PW; Sanders ME; Koopman WJ
    Clin Exp Rheumatol; 1993; 11 Suppl 8():S153-9. PubMed ID: 8100752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
    Choy EH; Panayi GS; Emery P; Madden S; Breedveld FC; Kraan MC; Kalden JR; Rascu A; Brown JC; Rapson N; Johnston JM
    Rheumatology (Oxford); 2002 Oct; 41(10):1142-8. PubMed ID: 12364634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with a chimeric CD4 monoclonal antibody is associated with a relative loss of CD4+/CD45RA+ cells in patients with rheumatoid arthritis.
    van der Lubbe PA; Breedveld FC; Tak PP; Schantz A; Woody J; Miltenburg AM
    J Autoimmun; 1997 Feb; 10(1):87-97. PubMed ID: 9080303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric monoclonal CD4 antibody--a novel immunosuppressant for clinical heart transplantation.
    Meiser BM; Reiter C; Reichenspurner H; Uberfuhr P; Kreuzer E; Rieber EP; Riethmüller G; Reichart B
    Transplantation; 1994 Aug; 58(4):419-23. PubMed ID: 7915442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.
    Lindsey JW; Hodgkinson S; Mehta R; Mitchell D; Enzmann D; Steinman L
    Ann Neurol; 1994 Aug; 36(2):183-9. PubMed ID: 8053654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.